Index

AAAs see arterioarterial anastomoses
( AAAs) AAV (adeno-associated virus) in gene therapy 421, 423, 425
ABC transporters 391
ABO antigens 55
abortion, induced (termination of pregnancy) 141, 222, 225, 427
abortion, spontaneous, due to infections 209–10, 212
acardiac anomaly see twin reversed arterial perfusion (TRAP)
acrocallosal syndrome 304
acilocirv 214
adeno-associated virus (AAV) in gene therapy 421, 423, 425
adenosine 80, 82, 84, 94
adenovirus in gene therapy 423
adrenal gland neuroblastoma 322, 336–7
adult stem cells 390, 399–401, 408–9 see also stem cells
AF (atrial fibrillation) 254
AET (atrial ectopic tachycardia) 254
AFP see alpha-fetoprotein
agalilie syndrome 118
alcohol consumption 358–9, 84
aldosterone 150
alloimmune disease see hemolytic disease of the fetus and newborn (HDFN); thrombocytopenia, alloimmune
alpha-fetoprotein (AFP) heptoblastoma 326
IUGR 350
parvovirus B19 infections 210
alpha thalassemia 63, 402, 418, 419
alveolar epithelial cells (AEs) 272, 276
amiodarone 80, 82, 83–4, 94
amniocentesis
diagnostic in HDFN 58
in IUGR 360
in viral infections 216, 229
therapeutic see amnioreduction
amniocentesis 141–2, 248, 278
amnion, water flow across 132
amnioreduction 139–40 in CCAM 288
in TTTS 4, 166, 170, 173, 185
amnion bands
NTDs 306
pseudo-amniotic band syndrome 174, 178
amniotic fluid (AF)
composition 128
flow 131, 133
inflow 131
outflow 132–3
infectious agents in CMV 219
rubella 229
toxoplasmosis 223–4
as route of administration for gene therapy 419
as a source of cells for tissue engineering 408–9
volume 128, 137
as a marker of renal function 246
measurement of 137–8
see also oligohydranmios; polyhydramnios
amniotic fluid index (AFI) 137–8, 139
anemia
after LCPV 179
alpha thalassemia 63
immune see hemolytic disease of the fetus and newborn (HDFN)
parvovirus B19 and hydrops 62–3, 209, 210
anencephaly 301, 307
anesthesia
fetal 254, 315
maternal 177, 314–15
aneuploidy
congenital heart disease 116
fetal hydrothorax (pleural effusion) 282
IUGR 359, 360
karyotyping 119, 247–8
NTDs 303–4
TRAP twins 190
tumors 320, 321
urinary tract obstruction 247–8, 255
angioarchitecture of the placenta see placenta, angioarchitecture
angiogenesis 401
placental 146, 149
angiotensin I/II in TTTS 150, 167
in urinary tract obstruction 241, 242–3
ANP (atrial natriuretic peptide) 151–2
antiarrhythmic agents 80–1, 92–4
adenosine 80, 84, 94
adverse effects 82, 83–4
amiodarone 80, 83–4, 94
classification 78
digoxin 80–1, 82, 93–4
factors affecting fetal response 80
flecainide 80–1, 82–3, 93–4
sotalol 80–1, 83, 93–4
antibiotics 225, 226
antibodies
maternal in alloimmune thrombocytopenia 68, 70
in autoimmune AV block 96, 97
in HDFN 57–8, 62
production by B cells 201, 203
therapeutic see immunoglobulin therapy
anticoagulants in IUGR 351, 363–4
post-delivery 364
anti-D prophylaxis 57
antidepressants 359
anti-epileptic drugs 305–6
antigen-presenting cells see dendritic cells
anti-1a antibodies 96, 97
anti-Müllerian hormone (AMH) 34
antioxidant enzymes, pulmonary 372
anti-Ro antibodies 96, 97
aortic abnormalities in acardiac fetuses 190
aortic valve
bicuspid 108–9
stenosis (in HLHS) 123–5
Apert syndrome 304
aquaporins 130–1, 132–3
array comparative genomic hybridization (CGH) 119–20
arrhythmias see dysrhythmias
arterioarterial anastomoses (AAAs) 158–9
arterioarterial anastomoses (AAAs) 158–9, 160–1
in TAPS 148
in TRAP 188
in TTTS 146–7, 148, 158–9, 161–3
arteriovenous (AV) anastomoses 157–8, 160–1
in TAPS 147
in TRAP 188–9
in TTTS 4, 148, 161–3
atrial flutter (AF)
atrial ectopic tachycardia (AET)
aspirin
artificial reproductive technology (ART)
atrial situs inversus
atrial natriuretic peptide (ANP)
atrioventricular reentry tachycardia (AVRT)
autonomy
Australia, multicenter trials
AV As
(AV As) AV block
AVRT (atrioventricular reentry tachycardia)
AVSD (atrioventricular septal defect)
bigeminy
bicuspid aortic valve
bladder outlet obstruction
blood transfusion, fetal
BMP (bone morphogenetic protein)
Bloom syndrome
BNP (brain natriuretic peptide)
bronchopulmonary sequestration (BPS)
bronchogenic cysts
bronchopulmonary sequestration (BPS)
C-type natriuretic peptide (CNP)
calcium channel blockers (verapamil)
carbenzapine 305
cardiac disease
acardiac anomaly seen twin reversed arterial perfusion (TRAP)
dysrhythmias seen dysrhythmias after fetal infections 210, 228
structural seen congenital heart disease
in TTTS 149–50, 164, 166–8 after treatment 170–1 grading of severity 168–70
long-term impact 171
RAS system 150–1, 167
vasoactive peptides 151–2, 167
119–20
tumors 326
cardiac physiology 78–9, 87
cardiac progenitor cells 102
cardiac tissue engineering 394
cardiocriocography (non-stress test) 362
cardiovascular disease (CVD) in adults, effect of the fetal environment 12–20
animal studies 13–16
DOHaD hypothesis 12, 13, 20 epidemiology 12
fetal adaptive responses 16, 18–20
human studies 13, 14
catalase 372
β-catenin 30, 31
CCAM see congenital cystic adenomatoid malformation of the lung
CCAM volume ratio (CVR) 277, 287, 332–3
CD4+/CD8+ T cells 200–1, 202 CMV infections 203–4
HIV infections 204
toxoplasmosis 205
trypanosomiasis (T. cruzi) 205
CDH see congenital diaphragmatic hernia cell free fetal DNA (cfDNA) analysis 56–7, 70
cell membranes, water flux across 128–9
amnion 132
placenta 129–31
Centre for Mother, Infant, and Child Research (Canada) 434
central nervous system abnormalities in acardiac fetuses 190
brain tumors 323, 331
CMV infection 216, 218, 219
gene therapy targeted to the brain 420–1
parvovirus B19 infection 210
toxoplasmosis 224
see also neural tube defects
cervical tumors 325, 329–30, 411
Cesarean section in alloimmune thymobectomy 75
EXIT procedure 292, 295–7, 330
Chagas disease 205
CHAOs syndrome 293–7
chest volume, lung expansion and 275–6
chest wall deformities 377
Chiari II malformation 313, 316
chickenpox (varicella zoster) 211–15
clinical manifestations fetal/neonatal 212–13
maternal 212
diagnosis fetal 213
maternal 212
epidemiology 211–12
management 214–15, 217
vaccination 214–15
chickens, as models of fetal physiology 15
chimerism, in fetal stem cell therapy 394
China, multicenter trials 437
CHIPS trial (Control of Hypertension in Pregnancy Study) 356
chloride ions, in fetal lung liquid 273
cholesterol, in hedgehog signaling 27, 29
CHOP score (in TTTS) 168–9
chorioangiopagus parasiticus seen twin reversed arterial perfusion (TRAP)
chorion regression syndrome 344
chorionic villi 342–4
in IUGR 346–9
chorionic villus sampling (CVS) 70
chioroentinitis 24, 225, 226
Christmas disease (hemophilia B), gene therapy 417–19, 425
chromosomal abnormalities
analysis techniques 119–20, 247–8
CNVs and microdeletions 119, 20–1, 359
genetic diaphragmatic hernia 370, 377
congenital heart disease 116
fetal hydrothorax (pleural effusion) 282
IUGR 359, 360
NTDs 303–4
translocations 118

© in this web service Cambridge University Press

www.cambridge.org
chromosomal abnormalities (cont.)
TRAP twins 190
urogenital abnormalities, midline affects 7, 368–9, 397
urogenic tract obstruction 247–8, 255
urinary tract obstruction 247–8, 255
chronic intervillousis (CIV) 349
chylolithiasis, fetal see hydrothorax, fetal
clindamycin 225
clinical trials
ethics 43
for gene therapy 427
multicenter trials 433–4, 437–8
GONet 434–8
problems in design and execution 2, 414, 433
cloning
position 117
therapeutic 390
CMV see cytomegalovirus (CMV) infections
CNP (C-type natriuretic peptide) 151–2
cogulationpathy
DIC 333
hemophilia 417–19, 425
thrombocytopenia
classification 67
in congenital infections 63, 208, 220
neonatal 69, 75–6
see also thrombocytopenia, alloimmune

cognitive aspects of decision-making 46–9

cognitive function in spina bifida 311, 313
colon cancer 31
common arterial trunk 104–5
communication of risk 49–51
Comprehensive Clinical Research Network
(CCRN) (UK) 436
congenital cystic adenomatoid malformation
of the lung (CCAM) 277–8, 285–93, 326, 332–3
macroscopic 287, 288, 325
management 277–8, 287–93
microscopic 287, 288–9
congenital diaphragmatic hernia (CDH)
276–7, 370
animal models 7, 380–2
causes and risk factors 370–1
embryology 370
epidemiology 276, 370, 376
genetic defects 370, 377
imaging 8, 377–80
left ventricular hypoplasia 373
liver herniation 7, 378–9
and the lungs
antioxidant abnormalities 372
arrested development 371
hypoplasia 276, 279, 371
persistent pulmonary hypertension 277, 372–3
postnatal abnormalities 276–7, 371–2, 373, 376–7
surfactant deficiency 373
ventilation-induced injury 371–2
management
diaphragmatic repair 7, 381
gene therapy 418, 420
postnatal 277, 376, 384
tissue engineering 410–11
tracheal occlusion 7–9, 277, 279, 376, 381–4
congenital heart disease (CHD)
acardiac fetuses 190
atrial isomerism 104
atrial septal defect 107, 115
atrial situs inversus 104
atrioventricular block and 95
atrioventricular septal defect 106, 107–8
CCTGA 104
classification 102–4
common arterial trunk 104–5
DILV 106
DORV 104, 105–6
embryogenesis 100–2, 109–11, 118
epidemiology 113
ethics of fetal therapy 123
etiology 114
environmental (maternal) factors 113
identification of genes 117–18
HLHS 108, 123
with highly restrictive/intact atrial septum 125
with severe aortic stenosis 123–5
laterality abnormalities 104
left ventricular hypoplasia in CDH 373
LIVOT obstruction 115–16
PAIVS 126
tetralogy of Fallot 105
TA 106–7
tissue engineering for 411–12
valve abnormalities 106, 108–9, 412
ventricular septal defect 105, 106, 108
congenital high airway obstruction syndrome (CHASOS) 293–7
congenital-infantile fibrosarcoma 324
congenital pulmonary airway malformation (CPAM) 277–8, 285–93, 326, 332–3
BPS 285–6, 287, 326, 331–2
macroscopic 277–8, 287–93, 331–2, 333
microscopic 277–8, 287–93, 331–2, 333
microscopic CCAM 287, 288–9
congenital pulmonary lymphangiecstasis 282
congenital rubella syndrome 228
congenital varicella syndrome 212–13, 214
congenitally corrected transposition of the great arteries (CCTGA) 104
consent
for genetic testing 120
for maternal-fetal (open) surgery 290
for research procedures 42, 43–4
therapeutic misconception 42
see also decision-making
convergent-extension processes in embryogenesis 31
copy number variants (CNVs) 116, 119–20, 359
cordocentesis see fetal blood sampling
Cornella de Lange syndrome 357
corticotestroids
alloimmune thrombocytopenia 73
AV block 96–7
CCAM/CPAM 278, 288, 333
choleiretinosis 225
fetal immunosuppression 399
placental disease in IUGR 350
CPAM see congenital pulmonary airway malformation
craniosynostosis 24–5, 34
craniothelencephalic dysplasia 304
Curranio syndrome 304
CVR (CCAM volume ratio) 277, 287, 332–3
CVS (chorionic villus sampling) 70
cyclopa 27
cystatin-C 247
cystic fibrosis 418, 419–20
cystic hygroma 325
cystoscopy 254–8, 263, 265–6
cytokines 200, 201, 202, 204
cytomelaglic inclusion disease (CIDS 216
cytomegalovirus (CMV) infections 215–22
clinical presentation at birth 216–17
clinical trial 360
fetal 216
maternal 215–16
epidemiology 215
fetal immune response 203–4
IUGR and 360
management 221
fetal prognosis 217–20, 221–2
maternal therapy 220–1
cytotoxic T cells 201
Czeielsi-losonc syndrome 304
data safety and monitoring boards 43
De Lia, JE 4–5
De Sanctis–Cacchiione syndrome 357
decision-making 45–52
autonomy in 40, 49
case study 45–6, 51, 52
eliciting patients’ preferences 51
emotional factors 47–8
information processing 46–7
intuition vs. rationality 47
principles of shared decision-making 40, 49–52
understanding and assessing risk 48–51
dendritic cells (DCs) 200, 202
CMV infection 204
in stem cell therapy 394
dermatological disorders, gene therapy 418, 422
Desert hedgehog (Dhh) 26
desmopressin (dDAVP) 131
developmental origins of health and disease (DOHaD) hypothesis 12, 13, 20
adaptive responses 16–20
animal models 13–16
human studies 13, 14
dexamethasone
alloimmune thrombocytopenia 73
AV block 96–7
dextroposition/dextrocardia 104
diabetes mellitus
maternal, NTDs and 304–5, 308
stem cell therapy 401, 413
diaphragmatic hernia
congenital
diathery 195–6
diet, maternal
folic acid in 302–3, 305
and health of offspring in later life 13–14,
16–18
and IUGR 16–17, 358
DIGITAT trial (Disproportionate
Intrauterine Growth Intervention
Trial At Term) 362–3
digoxin 82
electrophysiological action 80, 82
in SVT 80–1, 82, 93–4
disseminated intravascular coagulation
(DIC) 333
distal villous hypoplasia 348
DK phocomelia syndrome 304
DNA, analysis of fetal DNA in maternal
plasma 56–7, 70
dogs, in stem cell research 397–8
DOHaD hypothesis see developmental
origins of health and disease
(DoHaD) hypothesis
Down syndrome 358
Doppler ultrasound 14
cardiac rhythm 88
fetal anemia/hydrops 58–60, 63, 211
IUGR 350, 362
lung vascularization in CDH 379–80
saccrococcygeal teratoma 339
TRAP 194–5
double inlet left ventricle (DILV) 106
double outlet right ventricle (DORV) 104,
105–6
drugs of abuse 359
Dubowitz syndrome 357
Duchenne muscular dystrophy 398
gene therapy 418, 421
ductus venosus Doppler 362
dysrhythmias
atrioventricular block 89, 95–7
geminy/trigeminy 89, 95
bradycardia 94, 94–7
diagnosis 87–9, 94–5
ectopic beats 89, 95
electrophysiology 78–9, 87
antiarrhythmic agents and 80
epidemiology 89
sinoatrial node development 109–10
sinus bradyarrhythmia 90–1
supraventricular tachyarrhythmia (SVT)
78, 79–80, 89–90
antiarrhythmic treatment 80–4, 92–4
surveillance only 91
ventricular tachycardia 91, 94
see also antiarrhythmic agents
Ebstain’s anomaly 109
echocardiography 87–8, 94–5, 360–1
echocardiographic cystic lesion 349
ECMO (extra corporeal membrane
oxygenation) 277, 384
etoderm 24, 32
ectopic beats 89, 95
EDA/EDAR signaling pathway 24
educational level and decision-making 47
ELASTIN gene 116
electrocardiography (ECG) 88–9
electrolytes in AF 128
in fetal lung liquid 273
in fetal urine 243, 246–7, 250
electrophysiology, myocardial 78–9, 87
antiarrhythmic agents and 80
embryology
diaphragm 370
early embryogenesis 24
heart 100–2, 109–10, 118
immune system 201–3, 399
lung 271–2, 371
arrested in CDH 371
placental vasculature 146
signaling pathways
FGF 24–5, 54–5, 272
hedgehog 26–30, 31, 35
mechanisms 25–6
mutations 24–5
Notch 35–7
TGFB/BMP 25, 26, 31–4, 149, 242
Wnt 30–1
urinary tract 31, 238, 239
embryonic stem cells (ES cells) 390
in-vitro assay 391, 392
in-vivo assay 392
SCT ES cells 390, 395
therapeutic uses 393, 394–5
problems 393–5
emotions in decision-making 47–8
encephalocoele 301, 304
see also neural tube defects
encephalopathy 418
endocardium 24
endothelial progenitor cells (EPCs) 400–1
endothelins (ET-1/ET-2/ET-3) 151–2, 167
epidemiology, cardiovascular disease 12
chickenpox 211–12
CMV 215
congenital diaphragmatic hernia 276, 370,
376
congenital heart disease 113
dysrhythmias 89
FNAlT 68
HDFN 55, 62
lung lesions 276, 277, 282, 287
neural tube defects 301, 311
parvovirus B19 62, 208–9
rubella 227
toxoplasmosis 222
varicella 222
fetal breathing movements (FBM) 275, 277
fetal endoscopic tracheal occlusion
(FETO) 8–9, 382–4
fetal heart rate see dysrhythmias
fetal hydrops see hydrops fetalis
fetal loss due to infections 209–10, 212
of one twin in TTTS 60, 176–7, 179
saccrococcygeal teratoma 338
fetal lung liquid 131, 272–5, 381
fetal and neonatal alloimmune
thrombocytopenia (FNAIT) 67–76
epidemiology 68
identifying at-risk pregnancies 69–70
immune mechanisms 68
management 70–1
corticosteroids 73
of delivery 75
in groups at high risk of ICH 74
in ICH 74–5
IVIG 72–3, 74, 75
methods compared 73–4
in neonates 75–6
platelet transfusions 71–2, 74, 75–6
fetal thrombotic vasculopathy (FTV) 349–50
fetomaternal hemorrhage 55
fetoscopy 175, 196

ethics 39
autonomy 40, 41, 49
beneficence 39–40, 41, 42–3
CHD treatment 123
gene therapy 427
genetic testing 120
guidelines for fetal intervention 1
nen in medical research 42–1, 43–4
clinical investigation stage 43
innovation stage 42–3
transition to clinical practice 43, 44
status of the fetus 40–1
stem cell research 414
evidence-based medicine 43
ex-utero intrapartum therapy (EXIT)
procedure 292, 295–7, 330
exploitation in research 42
extra corporeal membrane oxygenation
(ECMO) 277, 384
extra-villous cytrophoblast (EVT) 341,
342–3, 46
eye
chorioretinitis (toxoplasmosis) 224, 225,
226
congenital rubella syndrome 229
development 27
retinoblastoma 327
Fallot’s tetralogy 105
Fanconi syndrome 358
fetal blood sampling 20
alloimmune thrombocytopenia (with
IUPT) 71–2, 74
CMV infection 220
HDFN 58
parvovirus B19 infection 210
for renal function 264
rubella infection 229
toxoplasmosis 223
varicella infection 213
fetal breathing movements (FBM) 275, 277
fetal endoscopic tracheal occlusion
(FETO) 8–9, 382–4
fetal heart rate see dysrhythmias
fetal hydrops see hydrops fetalis
fetal loss due to infections 209–10, 212
of one twin in TTTS 60, 176–7, 179
saccrococcygeal teratoma 338
fetal lung liquid 131, 272–5, 381
fetal and neonatal alloimmune
thrombocytopenia (FNAIT) 67–76
epidemiology 68
identifying at-risk pregnancies 69–70
immune mechanisms 68
management 70–1
corticosteroids 73
of delivery 75
in groups at high risk of ICH 74
in ICH 74–5
IVIG 72–3, 74, 75
methods compared 73–4
in neonates 75–6
platelet transfusions 71–2, 74, 75–6
fetal thrombotic vasculopathy (FTV) 349–50
fetomaternal hemorrhage 55
fetoscopy 175, 196

Index
Index

fetus-in-fetu 321
fibroblast growth factor (FGF) 24–5, 34
in lung development 272
fibrosarcoma, congenital 324
fifth disease 208
first heart field (FHF) 100, 101, 103, 109
flecainide 82
electrophysiological action 80, 82
in SVT 80–1, 82–3, 93–4
fluid balance
in the amniotic cavity 128–33
AF inflow 131
AF outflow 132–3
membrane water flux 128–31
volume of water 128
renin–angiotensin system 150, 167
in TTE 150–1
fluorescent in-situ hybridization (FISH) 119
FNAlT see fetal and neonatal alloimmune thrombocytopenia
folate/folic acid 301–3, 305, 308
folic acid 225
Fraser syndrome 293
Freda, VJ 3
fringe proteins 35
Fryns microphthalmia syndrome 304
γT cells 201, 203–4, 205
gastrointestinal tract abnormalities 138
gene therapy
advantages of prenatal intervention 417
conditions treatable by 418
congenital diaphragmatic hernia 420
cystic fibrosis 419–20
genodermatoses 422
hemoglobinopathies 419
hemophilia 417–19, 425
TUGR, 422
lysosomal storage diseases 420–1
muscular dystrophy 421
eths 427
human trials 427–8
NIH advisory committee
recommendations 417
preclinical testing 427
problems 425–6
stem cells and 424–5
vectors 422–5, 426
GeneClinics database 117
genetics
in congenital diaphragmatic hernia 370, 377
in congenital heart disease 101, 113–17, 118
consent for genetic testing 120
in NTDs 303, 304, 307–8
online databases 117, 364
prenatal genetic diagnosis 428
problems with genetic testing 118–19, 120
regulation of gene expression 117
Rheus factor 56
techniques
array CGH 119–20
FISH 119
gene identification 117–18
genome sequencing 120
karyotyping 119, 247–8
in tumors 320
see also chromosomal abnormalities
genodermatoses 418, 422
germ cell tumors/teratomas 321, 329–30, 338–9
germ-line contamination after gene therapy 426
glutathione peroxidase 372
GONet (Global Obstetrics Network) 434–8
Grannum grading 349–50
graphical representations of risk 50–1
Gregory, John, on research ethics 41–2
Grigon's classification 255
GRIT (Growth Restriction Intervention Trial) 363
hamartoma 320
hepatic 326, 333, 334
Harrison, Michael 1
Hashimoto–Pritzker disease 323
HDFN see hemolytic disease of the fetus and newborn
head and neck tumors 325, 329–31, 411
health literacy 47
hearing loss, CMV infection 216–17, 219
heart conditions see entries at cardiac and cardiovascular
Hedgehog signaling pathway 26–30
and the FGF pathway 35
and the Wnt pathway 31
helped-dependent adenovirus in gene therapy 423
Helsinki Declaration 42
hemangioma 320
hepatic 333, 334
hematological disorders
thrombophilia 351, 356, 364
tumors 323
see also coagulopathy; thrombocytopenia, alloimmune
hematopoietic stem cells (HSCs) 391
embryogenesis 202
fetal 399–400
in–vitro assay 391–2
in–vivo assay 392
management with 394
in animals 398
hemoglobinopathies
alpha thalassemia 63
gene therapy 418, 419
parvovirus B19 infection in childhood 208
sickle cell disease 356, 402, 419
stem cell therapy 402, 419
hemolytic disease of the fetus and newborn
(HDFN) 55–62
etiology 55–6, 62
identifying at-risk pregnancies 56–7
Kell antigen 56, 60, 62
management
history of 2–4
IUT 3–4, 59–62
maternal IVIG/plasmapheresis 62
monitoring at-risk pregnancies 57–60, 62
prophylaxis 57
hemophilias 417–19, 425
hemorrhage
fetal/maternal 55
placental 349
see also intracranial hemorrhage
heparin
in IUGR 351, 363–4
post-delivery 364
hepatic fetal cell transplantation 401
hepatic herniation in CDH 378–8, 382
hepatic tumors 326, 333–4
hepatoblastoma 326, 333–4
herpes simplex virus in gene therapy 423
heterotaxia 104
heuristics in decision-making 47
Hippocratic Oath 39
histiotrophic nutrition 341
history of fetal therapy 1–9
HIV (human immunodeficiency virus) infection 204
HLHS see hypoplastic left heart syndrome
Hoechst 33342 dye 391
holoarcardia 190
Holt–Oram syndrome 119
homocysteine 303
Hong Kong, multicenter trials 437
HSCs see hematopoietic stem cells
human leukocyte antigens (HLA) 200
and FNAIT 68
in stem cell transplantation 399, 400
human platelet antigens (HPA) 68
genotyping 70
hydrocephalus 311
hydrocephrosis 247, 255, 263
hydrops fetalis in CCAM/CPAM/BPS 287, 331, 332–3
in fetal hydrothorax (pleural effusion) 278, 283
in HDFN 57, 61–2
parvovirus B19 infections 62, 63, 209, 210, 211
SVT and 79, 80, 93
tumors and 322, 323
hydrothorax, fetal 278, 282–5
management 278, 283–4
hygiene, prevention of toxoplasmosis 226
hyperimmune globulin (HIG) for CMV infection 220
see also immunoglobulin therapy, intravenous
hypertension
preeclampsia 356, 361, 364
pulmonary hypertension 276, 277, 372–3, 384
in TTTS 150–1, 167
hyperthermia 306, 308
hypohidrotic ectodermal dysplasia 24
hypoplastic left heart syndrome (HLHS) 108, 123
with highly restrictive/intact atrial septum 125
with severe aortic stenosis 123–5
hypoplastic right heart syndrome 126
hypothalamo-pituitary-adrenal axis 18
hypoxia, maternal 358
hypoxic ischemic encephalopathy 418
hysterotomy for CCAM/CPAM 289–92, 333
EXIT procedure 292, 295–7, 330
for LUTO 265
for NTD closure 6–7, 312–18, 413
procedure 315
ICH see intracranial hemorrhage
IDEAL model of surgical research 2
immune system
fetal 205
cell types 200–1
development 201–3, 399
response to congenital infections 203–5
tolerance 203, 394
gene therapy and 425, 426
maternal, in the placenta 344, 349–50
stem cell therapy and 394–5, 397, 398, 399, 402
treatment of immunodeficiency syndromes 397, 398, 401–2
immunization
chickenpox 214–15
rubella 230–1
toxoplasmosis 226
immunoglobulin therapy
for allogeneic thrombocytopenia 70, 72–4, 75
for AV block 97
for HDN 62
prophylaxis 57
for maternal CMV 220
for maternal varicella 214
IMPACT (Interdisciplinary Maternal Perinatal Australasian Clinical Trials) network 436
imprinting (parent of origin effects) 307, 359
in-utero transplantation (IUT) of stem cells 394, 398–9, 400, 401–2, 413
in-vitro fertilization 359
Indian hedgehog (Ihh) 26
indirect fluorescent antibody test (IFA) 222
indirect hemagglutination test (IHA) 222
indomethacin
AF volume reduction 131, 140
tocolysis 314
induced pluripotent stem (iPS) cells
generation of 25, 391
therapeutic uses 393, 395
problems 393–5
infections
chronic maternal infections 205
IUGR and 360
see also individual agents
information processing in the decision-making process 46–7
insertional mutagenesis in gene therapy 426
Institutional Review Boards 42
interferons (IFN) 200, 204
interleukins (IL) 200, 201, 202
international collaborations 434–8
International Fetal Medicine and Surgery Society guidelines 1
inter-villous thrombosis (IVT) 349
intracranial hemorrhage (ICH)
epidemiology 68
fetal thrombocytopenia and 67, 68, 69, 70
treatment 74–5
imaging 74, 75
intrafetal ablation in TRAP 196–7
intramembranous (IM) flow (amnion) 132–3
intraperitoneal fetal transfusion 3, 4, 60
intrauterine fetal death (IUFD)
due to infections 209–10, 212
of one twin in TTTS 60, 176–7, 179
sacroccocygeal teratoma 338
intrauterine growth restriction (IUGR) 355
causes and risk factors 16–17, 356–60
early-onset 141, 363–4
management 341, 361, 365
delivery 362–3
fetal assessment/monitoring 360–2, 363
gene therapy 418, 422
post-delivery 351, 364
postpartum maternal health and future pregnancies 364–5
prenatal maternal interventions 350, 351, 361, 363–4
placental pathology 344–50, 356, 358, 363
post-delivery examination 351, 364
screening/diagnosis 140, 350–1, 355–6, 361, 422
online resources 364
symmetric vs. asymmetric 355–6
intrauterine platelet transfusion (IUPIT) 71–2, 74
intrauterine transfusion (IUT) (red cells)
for alpha thalassemia 63
at earlier gestations (<22 weeks) 62
complications 61, 63
for HDN 3–4, 60–2
timing of second transfusion 59–60
outcomes 61–2, 63
for parvovirus B19 infection 63, 210
procedures 60–1
intravenous immunoglobulin therapy
see immunoglobulin therapy
intention in decision-making 47
iPS cells seen induced pluripotent stem (iPS)
cells
IUFD see intrauterine fetal death
IUGR see intrauterine growth restriction
IUPIT see intrauterine platelet transfusion
IUT see in-utero transplantation; intrauterine transfusion
IVIG see immunoglobulin therapy
JAM3 gene 116
Jarcho–Levin syndrome 304
Johanson–Blizzard syndrome 358
Joubert syndrome 304
karyotyping 119, 247–8
Kell antigen-induced HDFN 56, 60, 62
kidney
agenesis/dysgenesis 140–1, 293
biopsy 264–5
embryogenesis 31, 238
imaging 248, 335
obstructive nephropathy see renal pathology in urinary tract
obstruction
stem cell therapy 398
in TTTS 150
in TTTS clinical outcomes 174–5, 178
recurrence 179
in SFLP 170–1, 176–7
in stage I disease 185
complications
fetal/neonatal 178–9
maternal 178
history of the method 4–5, 175
operator experience 177–8
practical procedures 175–7, 178
selective (SFLP) 170–1, 176–7, 179
views of placenta after therapy 163
laser therapy in CCAM/CPAM/BPS 288–9, 331
laser therapy in TRAP
coaugulation of cord anastomoses 196
intrafetal ablation 196
lateral inhibition in notch signaling 35
left ventricular outflow tract (LVOT) obstruction 115–16
legal liability in research projects 41
Lehman’s syndrome 304
lentiviruses in gene therapy 423
leukemia 323
lidocaine 94
Liley, William 3
Liley charts 58
limb bud development 27, 28–30, 34–5
limb ischemia/loss after fetal therapy 174, 178
literacy (health literacy) 47
liver
fetal liver cell transplantation 401
herniated in CDH 7, 378–9
tumors 326, 333–4
llamas as models of fetal physiology 16
long QT syndrome 95
LOTUS study (long-term follow up after intrauterine transfections) 62
lower urinary tract obstruction (LUTO) cystoscopy 254–8, 263, 265–6
diagnosis and assessment 140, 247–50, 253–4, 255, 262–5
epidemiology 253, 261
natural history 246, 253, 261–2, 268
open surgery 263
pathology 239–40, 247, 253, 262
VAS 250–1, 258, 266–8
vesicocentesis 248, 263–4
lung
CCAM/CPAM 277–8, 285–9, 326
CHAOS 293–7
congenital diaphragmatic hernia
antioxidant abnormalities 372
arrested lung development 371
geneky 418, 420
imaging 377–8, 379–80
lung hypoplasia 276–7, 279, 371
postnatal abnormalities 276–7, 371–2, 373, 376–7
Index

lump (cont.)
surfactant deficiency 373
ventilation-induced injury 371–2
cystic fibrosis 418, 419–20
embryonic development 271–2, 371
arrested in CDH 371
expansion 275–6, 279
fetal hydrothorax (pleural effusion) 278, 282–5
management 278, 283–4
fetal lung liquid 131, 272–5, 381
gene therapy targeted to 419–20, 426
hyperplasia/over-expansion 279, 293
hypoplasia/under-expansion 276
amnioinfusion for prevention of 141–2, 278
CDH 276–7, 279, 371
hydrothorax 278
neuromuscular defects 278
oligohydramnios 141, 278
pleuropulmonary blastoma 325–6
pulmonary hypertension 276, 277, 372–3, 384
surfactant 373
lung-to-head ratio (LHR) 377–8
LUTO see lower urinary tract obstruction
lymphangiectasia 282
lymphangiomia 325
lymphocytes see B cells; NK cells; T cells
lysozyme storage diseases 418, 420–1
M-mode echocardiography 87
macrophages 200, 399
magnesium sulfate 94, 314
magnetic resonance imaging (MRI)
CMV infection 219, 221–2
genital diaphragmatic hernia 8, 378–9, 380
IUGR 351
lung
CCAM/CPAM/BPS 287, 332
CDH 378, 380
CHAOS 295
myelomeningocele 316
TRAP 195
tumors
head and neck 329, 330
kidney 335, 336
liver hemangioma 335
neuroblastoma 337
sacroccygeal teratoma 338
urinary tract obstruction 253–4, 263
magnetic resonance imaging 89
major histocompatibility complex see human
leukocyte antigens
massive perivillous fibrin deposition
(MPVD) 349
maternal blood
fetal cells in 409
fetal DNA in 56–7
maternal factors affecting health of offspring/fetus
and cardiovascular disease 13–14, 16–18
and congenital heart disease 113
and IUGR 16–17, 358
and NTDs 305
maternal risk in fetal therapy
ethics 42, 43, 290
fetal surgery for CPAM 291–2
for NTD closure 313–14, 315
matrix metalloproteinases (MMPs) 247
maximum vertical pool/pocket (MVP)
measurement 137–8
MCA Doppler see middle cerebral artery
(MCA) Doppler
Meckel–Gruber syndrome 304
megacystis 253, 256
mesenchymal stem cells (MSCs) 393, 398,
400, 402, 408
in the amniotic fluid 408–9
in tissue engineering 410, 411, 412–13
mesoblastic nephroma 323–4, 334, 335, 336
mesoderm 24, 25
methotrexate 306
methylene tetrahydrofolate reductase
(MTHFR) 303
MiCare (Canada) 435
mice
as models of fetal physiology 15
in stem cell research 397
microdeletion syndromes 116, 119–20, 359
microRNA
in regulation of gene expression 117
in vector targeting 424
middle cerebral artery (MCA) Doppler
in fetal anemia/hydrops 58–60, 63, 211
in IUGR 362
mirror syndrome (Ballantyne syndrome) 210
mitral valve abnormalities 109
tissue engineering 412
in TTTS 168, 169
MOMS (Management of Myelomeningocele)
trial 6–7, 316–17
Morgagni hernia 370
see also congenital diaphragmatic hernia
MPVF (massive peri-villus fibrin deposition) 349
MRI see magnetic resonance imaging
MSCs see mesenchymal stem cells
muco polysaccharidosis type VII 420–1
Mulibrey nanism syndrome 357
multiple pregnancies see twin pregnancies
muscular dystrophy 398
gene therapy 418, 421
MVP (maximum vertical pool/pocket)
measurement 137–8
myelomeningocele 301
fetal pathology 5–6, 312, 316
management 311
animal models 6, 311–12
fetal surgery 6–7, 312–18, 413
MOMS trial 6–7, 316–17
postnatal outcomes 311
after surgery 313, 317
myofibroma/myofibromatosis 325
National Institute of Child Health and
Human Development (NICHD) (USA) 434–5
National Institute for Health Research
(NIHR) (UK) 434, 435–6
National Organization for Rare Disorders
(NORD) (USA) 364
natural killer (NK) cells 201, 202, 205, 399
neonates
CMV infection 216–17
congenital diaphragmatic hernia 377
thrombocytopenia 69
toxoplasmosis 224–5, 226
urinary tract obstruction 253, 261
varicella 213
nephroblastoma (Wilms’ tumor) 324, 334–6
Netherlands, multicenter trials 436–7
neural crest cells 24, 101–2, 103, 105
neural stem cells 400, 413
neural tube
hedgehog signaling 27–8
neural tube defects (NTDs) see
apotaxic bands 306
chromosomal abnormalities 303–4
diabetes 304–5, 308
diagnosis 311
epidemiology 301, 311
fetal pathology 5–6, 312
folute and 301–3, 305, 308
genetics 303, 304, 307–8
hyperthermia 306, 308
iatrogenic causes 305–6
management 311
animal models 6, 311–12
fetal surgery 6–7, 312–18, 413
MOMS trial 6–7, 316–17
neural stem cells 413
maternal obesity 305
postnatal outcomes 311
after surgery 313, 317
prevention 301–3, 308
smoking 306
twin pregnancies 306–7
neuroblastoma 322, 336–7
New Zealand, multicenter studies 436
nitrile oxide (NO) 242, 277, 372, 373
NK (natural killer) cells 201, 202,
205, 399
NKKZ 2.5 gene 115, 118, 119
nonmaleficence 40
non-stress test 362
Noonan syndrome 116–17
Notch signaling pathway 35–7
NOTCH1 gene 116
NTDs see neural tube defects
numeracy and decision-making 47, 50
Nuremberg Code of research ethics 42
nutrition, maternal
folute 302–3, 305
and health of offspring in later life 13–14,
16–18
and IUGR 16–17, 358
obesity
childhood 13
maternal 13, 16, 305
oligohydramnios
causes 130, 140, 145, 243, 278
complications 141, 142
placenta in monzygotic twins
in TRAP 189
in TTTS 145, 156, 163–4
thrombosis/hemorrhage 349, 351, 358
Toxoplasma infection 223
water flux across 129–31
plasmapheresis, maternal
for AV block 97
for HDFN 62
platelets
antigens (HPA) 68
thrombocytopenia
classification 67
in congenital infections 63, 208, 220
neonatal 69, 75–6
see also thrombocytopenia, alloimmune
transfusions
intrauterine 71–2, 74
neonatal 75–6
pleural effusions (fetal hydrothorax) 278,
282–5
pleurodesis 284
pleuropertoneal membranes 370
pleuropulmonary blastoma 325–6
PLUG therapy (tracheal occlusion) 8, 277,
279, 381–2
FETO 8–9, 382–4
pluripotent stem cells
see embryonic stem cells
PLUTO trial (percutaneous shunting in
LUTO) 268
pneumonia, varicella 212
polyhydramnios
causes 130, 138, 145
classification 138
complications 138–9, 140
definition 138
diagnosis and assessment 137–8
management 139–40
in CCAM 288
in TTTS 4, 166, 170, 173, 185
polymerase chain reaction (PCR)
CMV 216, 219–20
parvovirus B19 209
rubella 229
toxoplasmosis 223–4
varicella 213
posterior urethral valves (PUV) 249, 253,
261, 263
cystoscopy 253, 257–8, 265–6
see also lower urinary tract obstruction
posthepatic mesenchymal plate 370
posture, fetal, lung expansion and 275, 278
PPROM see preterm premature rupture of
membranes
preconception counseling for alloimmune
thrombocytopenia 70
preconception folate supplements 301–3
prednisone 73
preeclampsia 356, 361, 364
pregnancy-associated placental protein A
(PAPP-A) 344, 350
pregnancy-associated progenitor cells 409
premature labor, and fetal surgery 314
prenatal genetic diagnosis (PGD) 428
preterm birth
maternal nutritional status 17–18
varicella 212
preterm premature rupture of membranes
(PPROM) amnioinfusion for treatment of 141–2,
248, 278
diagnosis 140
iatrogenic 178, 179, 195
PRIDE study (PR interval dexamethasone
evaluation) 97
primary fetal hydrothorax (PFHT) 278,
282–5
management 278, 283–4
primates, in stem cell research 397–8
probability and decision-making 48,
50–1
procainamide 84
proepicardial organ (PEO) 101, 102
progenitor cells 389
cardiac 102
endothelial 400–1
epithelial 401
pregnancy-associated 409
transdifferentiation 395
propranolol 94
prostaglandin synthetase inhibitors
AF volume reduction 131, 140
tocolysis 314
prune belly syndrome 253, 261
pseudo-amniotic band syndrome (PABS)
174, 178
pseudocardia 190
PTPN11 gene 116–17
PubMed database 364
pulmonary atresia with intact ventricular
septum (PAIVS) 226
pulmonary hypertension 276, 277, 372–3,
384
pulmonary hypoplasia 276
amnioinfusion for prevention of 141–2,
278
CDH 276–7, 279, 371
hydrothorax 278
neuromuscular defects 278
oligohydranmios 141, 278
pulmonary valve abnormalities
congenital 105, 106, 109, 412
in TTTS 168, 169, 171
pulsed wave Doppler (PWD) imaging 88
Purkinje fibers 110
PUV (posterior urethral valves) 249, 253,
261, 263
cystoscopy 255, 257–8, 265–6
see also lower urinary tract obstruction
pyrexia, NTDs and
257, 266
quinteto staging classification of TTTS 149,
168
radiofrequency ablation (RFA)
in CCAM 289
in TRAP 196, 197
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fetal blood sampling</td>
<td>58</td>
</tr>
<tr>
<td>Maternal antibodies</td>
<td>57–8</td>
</tr>
<tr>
<td>Ultrasound</td>
<td>58–60</td>
</tr>
<tr>
<td>Prophylaxis</td>
<td>57</td>
</tr>
<tr>
<td>Right ventricular outflow tract obstruction (RVOTO)</td>
<td>in TTTS 167–8, 169, 171</td>
</tr>
<tr>
<td>Risk, understanding of</td>
<td>48–51</td>
</tr>
<tr>
<td>RNA regulation of gene expression</td>
<td>117</td>
</tr>
<tr>
<td>In vector targeting</td>
<td>424</td>
</tr>
<tr>
<td>Roberts syndrome</td>
<td>358</td>
</tr>
<tr>
<td>Rodents</td>
<td>as models of fetal physiology</td>
</tr>
<tr>
<td>In stem cell research</td>
<td>397</td>
</tr>
<tr>
<td>Royal College of Obstetricians and Gynaecologists (RCOG) (UK)</td>
<td>434, 436</td>
</tr>
<tr>
<td>RSmads, in TGF beta signaling</td>
<td>33–4</td>
</tr>
<tr>
<td>Rubella</td>
<td>226–31</td>
</tr>
<tr>
<td>Clinical manifestations</td>
<td>fetal/neonatal 228–9</td>
</tr>
<tr>
<td>Maternal 227</td>
<td></td>
</tr>
<tr>
<td>Diagnosis</td>
<td>fetal 229–30</td>
</tr>
<tr>
<td>Maternal 228</td>
<td></td>
</tr>
<tr>
<td>Epididymitis</td>
<td>227</td>
</tr>
<tr>
<td>Vaccination</td>
<td>229–30</td>
</tr>
<tr>
<td>Vertical transmission</td>
<td>228</td>
</tr>
<tr>
<td>Rubenstein–Tybii syndrome</td>
<td>357</td>
</tr>
<tr>
<td>Russell–Silver syndrome</td>
<td>357, 359</td>
</tr>
<tr>
<td>Sabin–Feldman dye test</td>
<td>222</td>
</tr>
<tr>
<td>Sacroccygeal teratoma</td>
<td>321, 322, 338–9</td>
</tr>
<tr>
<td>Salbutamol</td>
<td>97</td>
</tr>
<tr>
<td>SAN (sino–atrial node)</td>
<td>109–10</td>
</tr>
<tr>
<td>Sarcomas</td>
<td>324–5</td>
</tr>
<tr>
<td>Sclerotherapy</td>
<td>in CCAM 289</td>
</tr>
<tr>
<td>For pleural effusion</td>
<td>284</td>
</tr>
<tr>
<td>Sclerotome development</td>
<td>27</td>
</tr>
<tr>
<td>Sclerotherapy</td>
<td>284</td>
</tr>
<tr>
<td>Seckel syndrome</td>
<td>357</td>
</tr>
<tr>
<td>Second heart field (SHF)</td>
<td>101, 103</td>
</tr>
<tr>
<td>Malformations derived from</td>
<td>104–8, 109</td>
</tr>
<tr>
<td>Seldinger technique</td>
<td>175</td>
</tr>
<tr>
<td>Selective fetoscopic laser photocoagulation (SFLP/S LPCV)</td>
<td>170–1, 176–7, 179</td>
</tr>
<tr>
<td>Self-renewal of stem cells</td>
<td>389–90</td>
</tr>
<tr>
<td>Septostomy</td>
<td>170, 173–4</td>
</tr>
<tr>
<td>Septum transversum</td>
<td>370</td>
</tr>
<tr>
<td>Serine-threonine kinase receptors</td>
<td>31</td>
</tr>
<tr>
<td>Serology</td>
<td>CMV 215–16</td>
</tr>
<tr>
<td>Parvovirus B19</td>
<td>209, 210–11</td>
</tr>
<tr>
<td>Rubella</td>
<td>227, 228, 229</td>
</tr>
<tr>
<td>Toxoplasmosis</td>
<td>222–3</td>
</tr>
<tr>
<td>Varicella</td>
<td>212, 213</td>
</tr>
<tr>
<td>Severe combined immunodeficiency (SCID)</td>
<td>397, 398, 401–2, 418</td>
</tr>
<tr>
<td>Shared decision-making</td>
<td>40, 49–52</td>
</tr>
<tr>
<td>Communicating risk information</td>
<td>49–51</td>
</tr>
<tr>
<td>Eliciting patients’ preferences</td>
<td>51</td>
</tr>
<tr>
<td>Making the decision</td>
<td>51–2</td>
</tr>
<tr>
<td>Sheep</td>
<td>as models of fetal physiology</td>
</tr>
<tr>
<td>In stem cell research</td>
<td>397–8</td>
</tr>
<tr>
<td>Sh</td>
<td>see Sonic hedgehog</td>
</tr>
<tr>
<td>Shingles (zoster)</td>
<td>212, 213</td>
</tr>
<tr>
<td>Sickle cell disease</td>
<td>356, 402, 419</td>
</tr>
<tr>
<td>Siegel-Bartelt syndrome</td>
<td>304</td>
</tr>
<tr>
<td>Signaling pathways</td>
<td>angiogenesis (placental)</td>
</tr>
<tr>
<td>FGFI 24–5, 34–5, 272</td>
<td></td>
</tr>
<tr>
<td>Hedgehog 26–30, 31, 35</td>
<td></td>
</tr>
<tr>
<td>In lung development</td>
<td>271</td>
</tr>
<tr>
<td>Mechanisms</td>
<td>25–6</td>
</tr>
<tr>
<td>Mutations causing disease</td>
<td>24–5</td>
</tr>
<tr>
<td>BMP 34</td>
<td></td>
</tr>
<tr>
<td>FGFI 24–5, 34, 272</td>
<td></td>
</tr>
<tr>
<td>Hedgehog 27–8, 29, 30</td>
<td></td>
</tr>
<tr>
<td>Notch 37</td>
<td></td>
</tr>
<tr>
<td>Wnt 31</td>
<td></td>
</tr>
<tr>
<td>Notch 35–7</td>
<td></td>
</tr>
<tr>
<td>TGFbeta/BMP 25, 26, 31–4, 149, 242</td>
<td></td>
</tr>
<tr>
<td>Wnt 30–1</td>
<td></td>
</tr>
<tr>
<td>Silencing of gene therapy vectors</td>
<td>424</td>
</tr>
<tr>
<td>Single umbilical artery (SUA)</td>
<td>157</td>
</tr>
<tr>
<td>Sino–atrial node (SAN)</td>
<td>109–10</td>
</tr>
<tr>
<td>Sinus bradycardia</td>
<td>95</td>
</tr>
<tr>
<td>Sinus tachycardia</td>
<td>90–1</td>
</tr>
<tr>
<td>Skeletal dysplasia</td>
<td>BMP family mutations</td>
</tr>
<tr>
<td>FGFI signaling 24–5, 34</td>
<td></td>
</tr>
<tr>
<td>See also osteogenesis imperfecta</td>
<td></td>
</tr>
<tr>
<td>Skin disorders, gene therapy</td>
<td>418, 422</td>
</tr>
<tr>
<td>Slapped cheek syndrome (fifth disease)</td>
<td>208</td>
</tr>
<tr>
<td>SlaIaI gene</td>
<td>118</td>
</tr>
<tr>
<td>Smads, in TGFbeta signaling</td>
<td>33–4</td>
</tr>
<tr>
<td>Small-for-gestational-age (SGA)</td>
<td>355, 361</td>
</tr>
<tr>
<td>See also intrauterine growth restriction</td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td>and IUGR 358, 361</td>
</tr>
<tr>
<td>and NTDs 306</td>
<td></td>
</tr>
<tr>
<td>Smoothened (Smo) receptor</td>
<td>27</td>
</tr>
<tr>
<td>Solomon technique</td>
<td>177, 179</td>
</tr>
<tr>
<td>Somatic cell nuclear transfer (SCNT) ES cells</td>
<td>390, 395</td>
</tr>
<tr>
<td>SCOPE study 436</td>
<td></td>
</tr>
<tr>
<td>Seckel syndrome</td>
<td>357</td>
</tr>
<tr>
<td>Somatic stem cells 390, 399–401, 408–9</td>
<td></td>
</tr>
<tr>
<td>See also stem cells</td>
<td></td>
</tr>
<tr>
<td>Somites</td>
<td>36–7</td>
</tr>
<tr>
<td>Sonic hedgehog (Shh)</td>
<td>26–30</td>
</tr>
<tr>
<td>and the FGF pathway</td>
<td>35</td>
</tr>
<tr>
<td>and the Wnt pathway</td>
<td>31</td>
</tr>
<tr>
<td>Sotalol 82</td>
<td></td>
</tr>
<tr>
<td>Electrophysiological action</td>
<td>80, 83</td>
</tr>
<tr>
<td>In SVT 80–1, 83, 93–4</td>
<td></td>
</tr>
<tr>
<td>Southampton Women’s Survey</td>
<td>13</td>
</tr>
<tr>
<td>Spina bifida</td>
<td>303</td>
</tr>
<tr>
<td>Embryogenesis</td>
<td>31, 301</td>
</tr>
<tr>
<td>Fetal pathology</td>
<td>5–6, 312, 316</td>
</tr>
<tr>
<td>Management</td>
<td>311</td>
</tr>
<tr>
<td>Animal models</td>
<td>6, 311–12</td>
</tr>
<tr>
<td>Fetal surgery</td>
<td>6–7, 312–18, 413</td>
</tr>
<tr>
<td>MOMS trial</td>
<td>6–7, 316–17</td>
</tr>
<tr>
<td>Neural stem cells</td>
<td>413</td>
</tr>
<tr>
<td>Postnatal outcomes</td>
<td>311</td>
</tr>
<tr>
<td>After surgery</td>
<td>313, 317</td>
</tr>
<tr>
<td>See also neural tube defects</td>
<td></td>
</tr>
</tbody>
</table>

© in this web service Cambridge University Press www.cambridge.org
Index

tumors (cont.)
liver 326, 333–4
management postnatal 330, 331–2, 333, 334, 336, 337, 339
prenatal 330, 331, 333, 334, 335–6, 337, 338–9
neuroblastoma 322, 336–7
pleuropulmonary blastoma 325–6
retinoblastoma 327
soft tissue 324–5
teratomas 321, 329–30, 338–9
see also congenital pulmonary arterial malformation Turner syndrome 116
twin anemia–polycythemia sequence (TAPS) 147–8, 179
twin oligohydramnios–polyhydramnios sequence (TOPS) see twin-to-twin transfusion syndrome twin pregnancies
AF volume estimation 137
IUGR and 359–60
NTDs and 306–7
twin reversed arterial perfusion (TRAP) 187
acardiac twin 188, 189–90, 193, 194
aneuploidy 190
diagnosis 190–1, 194–5
management 191, 195–8
pathology 187–9, 193
placentaion 189
SUA 157
prognosis 191, 195
"pump" twin 189, 191, 195
twin-to-twin transfusion syndrome (TTTS) 145
cardiovascular changes 149–50, 164, 166–8 after treatment 170–1
grading of severity 168–70
long-term impact 171
RAS system 150–1, 167
vasoactive peptides 151–2, 167
loss of one twin 160, 176–7, 179
management
amnioreduction 4, 166, 170, 173, 185
complications 140, 174, 178–9, 185
history 4–5, 175
laser therapy 4–5, 163, 170–1, 174–9, 185
septostomy 170, 173–4
in stage I disease 179–80, 185–6
placenta 145, 156, 163–4
angiarchitecture 4, 145–7, 148, 149, 156–63
severity/staging 149, 168–70, 184
stage I disease
clinical features 185
management 179–80, 185–6
progression 179, 184–5
survival rates 157, 170, 173, 176–7, 184
ultrasound
3D 195, 345, 378
AF volume estimation 137–8
bladder 140, 248–9
congenital diaphragmatic hernia 377–8, 379–80
echocardiography 87–8, 94–5, 360–1
fetal anemia/hydrops 58–60, 63, 210, 211
fetal well-being 14
head and neck tumors 329, 331
infections
CMV 219, 221
parvovirus B19 219
rubella 229
toxoplasmosis 224
varicella 213
IUGR 345, 349–51, 355–6, 362
kidney 248
liver tumors 334
lung
CCAM/CPAM/BPS 286, 287, 331, 332
CDH 377–8, 379–80
CHAOS 293
hydrothorax 283
neuroblastoma 336–7
saccroccogygeal teratoma 339
TRAP 190–1, 194–5
urinary tract obstruction 140, 248–9, 253, 255, 262–3
umbilical arteries
in IUGR 140, 349, 361, 362
single (SUA) 157
in TRAP 157, 187
in TTTS 149
umbilical cord
asymmetric insertion in MC twins/TTTS 147, 156–7, 161
occlusion as therapy for TRAP 195–6
underweight mothers 13
United Kingdom (UK), multicenter trials 434, 435–6
United States of America (USA)
NICHD and multicenter trials 434–5
regulation of tissue-engineered products 413–14
upper airway obstruction
CHAOS 293–7
lung expansion and 276
urea cycle defects 418
ureteral obstruction 238–9
see also urinary tract obstruction, renal pathology
urethral atresia (UA) 249, 253, 255
urethral obstruction see urinary tract obstruction, lower
urinary tract obstruction
animal models 238–9, 240–2, 243, 262
embryogenesis 238, 239
lower (LUTO)
cystoscopy 254–8, 263, 265–6
diagnosis and assessment 140, 247–50, 253–4, 255, 262–5
epidemiology 253, 261
natural history 246, 253, 261–2, 268
open surgery 265
pathology 239–40, 247, 253, 262
VAS 250–1, 258, 266–8
vesicocentesis 248, 263–4
renal pathology 238, 240, 243, 262
angiotensin II inhibition 242–3
animal models 238–9, 262
effect on contralatral kidney 243
hydro nephrosis 247, 255, 263
interstitial changes 241–2
nephron loss 240–1
tubular cell death 241
upper 238–9
urine, fetal
AF volume and 131, 243
analysis after vesicocentesis 249–50, 263–4
effect of indomethacin 131, 140
erytroleys 243, 246–7, 250
renal function markers 243, 246–7, 250
uterine artery Doppler, and IUGR 350
teroplastical vascular insufficiency (UPVI) 356–8, 361–2, 422
see also intrauterine growth restriction
vaccination
chickenpox 214–15
rubella 230–1
toxoplasmosis 226
valaciclovir 220–1
valproic acid 305
varicella zoster see chickenpox
VAS (vesico-amniotic shunt) 250–1, 258, 266–8
vascular endothelial growth factors (VEGFs)
AF volume and 132
gene therapy in IUGR 422
in placental angiogenesis 149
uterine vasodilatation 18
vascular-ster phenomenon 189
vasculogenesis 146
see also angiogenesis
vasodilators
in IUGR 364
maternal adaptive response 18–19
in pulmonary hypertension 277, 372, 373
VEGFs see vascular endothelial growth factors
velamentous cord insertion 147, 156–7
venovenous anastomoses (VVAs) 159–63
ventilation, in congenital diaphragmatic hernia 277, 371–2, 376, 384
ventricular dysfunction in TTTS 150, 167–8 after treatment 170–1
ventricular hypoplasia 373
ventricular septal defect (VSD) 105, 106, 108
ventricular tachycardia (VT) 91, 94
verapamil 79, 84
vertical transmission
chickenpox 212
CMV 215, 217, 218
HIV 204
parvovirus B19 208, 209
rubella 228

### Index

<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toxoplasma</td>
<td>223</td>
</tr>
<tr>
<td>vesicoamniotic shunt (VAS)</td>
<td>250–1, 258,</td>
</tr>
<tr>
<td></td>
<td>266–8</td>
</tr>
<tr>
<td>vesicocentesis</td>
<td>248, 263–4</td>
</tr>
<tr>
<td>villi, placental</td>
<td>342–3</td>
</tr>
<tr>
<td>CVS in alloimmune disease</td>
<td>70</td>
</tr>
<tr>
<td>in IUGR</td>
<td>346–9</td>
</tr>
<tr>
<td>villitis of unknown etiology (VUE)</td>
<td>349</td>
</tr>
<tr>
<td>villous cytotrophoblast</td>
<td>343–4</td>
</tr>
<tr>
<td>vision, loss of</td>
<td>224, 229</td>
</tr>
<tr>
<td>vitamins</td>
<td></td>
</tr>
<tr>
<td>A, deficiency</td>
<td>370–1</td>
</tr>
<tr>
<td>folate</td>
<td>301–3, 305, 308</td>
</tr>
<tr>
<td>Waardenburg syndrome</td>
<td>304</td>
</tr>
<tr>
<td>water balance see fluid balance weight, maternal</td>
<td>13, 16, 305</td>
</tr>
<tr>
<td>William syndrome</td>
<td>116</td>
</tr>
<tr>
<td>Wilms' tumor</td>
<td>324, 334–6</td>
</tr>
<tr>
<td>Wnt signaling pathway</td>
<td>30–1</td>
</tr>
<tr>
<td>X-severe combined immunodeficiency (X-SCID)</td>
<td>397, 398, 401–2, 418</td>
</tr>
<tr>
<td>xenografts (human–mouse)</td>
<td>392</td>
</tr>
<tr>
<td>yolk sac tumors</td>
<td>321</td>
</tr>
<tr>
<td>zebrafish, as models of fetal physiology</td>
<td>15</td>
</tr>
<tr>
<td>zinc finger transcription factors (Gli1/Gli2/Gli3)</td>
<td>27, 28, 29–30</td>
</tr>
<tr>
<td>zoster (shingles)</td>
<td>212, 213</td>
</tr>
</tbody>
</table>